BACKGROUND: In recent decades, extensive resources have been invested to develop cellular, molecular and genomic technologies with clinical applications that span the continuum of cancer care. METHODS: In December 2006, the National Cancer Institute sponsored the first workshop to uniquely examine the state of health services research on cancer-related cellular, molecular and genomic technologies and identify challenges and priorities for expanding the evidence base on their effectiveness in routine care. RESULTS: This article summarizes the workshop outcomes, which included development of a comprehensive research agenda that incorporates health and safety endpoints, utilization patterns, patient and provider preferences, quality of care and access, disparities, economics and decision modeling, trends in cancer outcomes, and health-related quality of life among target populations. CONCLUSIONS: Ultimately, the successful adoption of useful technologies will depend on understanding and influencing the patient, provider, health care system and societal factors that contribute to their uptake and effectiveness in 'real-world' settings. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: In recent decades, extensive resources have been invested to develop cellular, molecular and genomic technologies with clinical applications that span the continuum of cancer care. METHODS: In December 2006, the National Cancer Institute sponsored the first workshop to uniquely examine the state of health services research on cancer-related cellular, molecular and genomic technologies and identify challenges and priorities for expanding the evidence base on their effectiveness in routine care. RESULTS: This article summarizes the workshop outcomes, which included development of a comprehensive research agenda that incorporates health and safety endpoints, utilization patterns, patient and provider preferences, quality of care and access, disparities, economics and decision modeling, trends in cancer outcomes, and health-related quality of life among target populations. CONCLUSIONS: Ultimately, the successful adoption of useful technologies will depend on understanding and influencing the patient, provider, health care system and societal factors that contribute to their uptake and effectiveness in 'real-world' settings. Copyright 2009 S. Karger AG, Basel.
Authors: Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar Journal: PLoS Med Date: 2007-08 Impact factor: 11.069
Authors: Muin J Khoury; Steven B Clauser; Andrew N Freedman; Elizabeth M Gillanders; Russ E Glasgow; William M P Klein; Sheri D Schully Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-27 Impact factor: 4.254
Authors: Fiona A Miller; Robin Z Hayeems; Jessica P Bytautas; Philippe L Bedard; Scott Ernst; Hal Hirte; Sebastien Hotte; Amit Oza; Albiruni Razak; Stephen Welch; Eric Winquist; Janet Dancey; Lillian L Siu Journal: Eur J Hum Genet Date: 2013-07-17 Impact factor: 4.246
Authors: Christine B Weldon; Julia R Trosman; William J Gradishar; Al B Benson; Julian C Schink Journal: J Oncol Pract Date: 2012-05-22 Impact factor: 3.840
Authors: Fiona A Miller; Paul Krueger; Robert J Christensen; Catherine Ahern; Ronald F Carter; Suzanne Kamel-Reid Journal: BMC Health Serv Res Date: 2009-07-30 Impact factor: 2.655
Authors: Muin J Khoury; Colleen M McBride; Sheri D Schully; John P A Ioannidis; W Gregory Feero; A Cecile J W Janssens; Marta Gwinn; Denise G Simons-Morton; Jay M Bernhardt; Michele Cargill; Stephen J Chanock; George M Church; Ralph J Coates; Francis S Collins; Robert T Croyle; Barry R Davis; Gregory J Downing; Amy Duross; Susan Friedman; Mitchell H Gail; Geoffrey S Ginsburg; Robert C Green; Mark H Greene; Philip Greenland; Jeffrey R Gulcher; Andro Hsu; Kathy L Hudson; Sharon L R Kardia; Paul L Kimmel; Michael S Lauer; Amy M Miller; Kenneth Offit; David F Ransohoff; J Scott Roberts; Rebekah S Rasooly; Kari Stefansson; Sharon F Terry; Steven M Teutsch; Angela Trepanier; Kay L Wanke; John S Witte; Jianfeng Xu Journal: Genet Med Date: 2009-08 Impact factor: 8.822